Key facts
- It has raised $66.3M; the latest was Early Stage VC ($66.3M) in Nov 2025.
- Notable investors include General Catalyst, Cherry Ventures, Starbloom Capital, Jade Cove Partners, Puzzle Ventures (Berlin).
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Integral
- ·The full record, as it builds
Funding rounds
No funding rounds for Integral are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Integral
Developer of advanced medical technologies designed to treat neurological and psychiatric disorders. The company's platform features a miniaturized, implanted deep-brain interface capable of recording and modulating neural activity while monitoring symptoms, enabling healthcare providers to deliver effective treatments and gain insights into the biological causes of brain disorders, improving the quality of care for affected individuals.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2024
- Employees
- 10
- Website
- integralneuro.com/
- Ownership
- Privately Held (backing)
Integral doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Integral shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Integral in its N-PORT filings yet. We sweep new filings monthly.